Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Open accessThe DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Abstract
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint blockade through targeting programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects in cancer immunotherapy of many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability. In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy. We also discuss the adverse events associated with PD-1/L1/2 inhibitors, ranging from severe life-threatening conditions such as autoimmune myocarditis to mild and moderate reactions such as skin rashes, and explore the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neutralizing antibodies for the PD-1/PD-L1 interaction or for CTLA4 restores the cytotoxic activity of T-cells, which induces T-cell mediated tumor cell destruction, and have transformed the cancer treatment landscape (Table 1) [82].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [82]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 1×
“Since highly mutated tumors show a favorable response to therapy, more insight is needed at the gene level to determine the mutations which are proresponsive and thus have the potential to be used as predictive biomarkers [107].”
BackgroundPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 1×
“In the management of advanced metastatic melanoma, pembrolizumab has improved the overall survival of patients, with relatively minimal toxicity [44].”
BackgroundGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Similar findings were observed in the gut microbiome profile of patients with hepatocellular carcinoma (HCC) [109] and melanoma [110] who were treated with anti-PD-1 immunotherapy.”
ResultPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“A few years later, in 1999, researchers demonstrated that PD-1-knockout mice developed lupus-like autoimmune syndromes, signifying that PD-1 acts as an immune checkpoint [7, 8].”
BackgroundPI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“Checkpoint immunotherapy is highly specific to the target cells [60]; hence, accompanied by less hazardous side effects [61].”
BackgroundCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,364
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · cited 3×
“PD-1 blocker agents are reported to be associated with higher rates of disease recurrence compared with CTLA-4 inhibitors [12].”
BackgroundCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · cited 1×
“[14, 125] found that cancers that expressed PDL-1 receptors were more responsive to treatment with single-agent PD-1 blockers than tumors without PDL-1 expression.”
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215
Mass Cytometry: Single Cells, Many Features
Spitzer, M. H., & Nolan, G. P. (2016) · Cell · doi:10.1016/j.cell.2016.04.019 · Cited by 1,199
Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G., Malboeuf, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0134-3 · Cited by 1,157
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · cited 1×
“Incorporating high-resolution assays including single-cell gene expression profiling, T cell repertoire sequencing, whole-exome sequencing (WES), and targeted sequencing on circulating tumor cells (CTCs), cell-free DNA (cfDNA), and tumor tissue may shape the future of precision medicine by identification of genes in b…”
BackgroundKamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854 · cited 1×
“PD-1/L1/2 checkpoint inhibitors block this pathway [24], increasing immune cell proliferation, and enhancing the efficacy of the body’s natural antitumor surveillance system [20, 25, 26].”
BackgroundSheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · cited 1×
“This process eventually inhibits cytokine production, T cell proliferation, and survival through downregulating transcription of the prosurvival factor Bcl-XL [27, 30] (Figure 2).”
BackgroundDavies, M. A., Saiag, P., Robert, C., Grob, J.-J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30429-1 · Cited by 766
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735 · cited 1×
“In another study, which used high-dimensional single-cell mass cytometry, the frequency of CD14+CD16−HLA-DRhi monocytes before treatment was found to be a predictor of response to anti-PD-1 immunotherapy in patients with melanoma [147].”
BackgroundDomingues, B., Lopes, J., Soares, P., & Populo, H. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s134842 · Cited by 701
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 696
Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., Rathkopf, D., Morris, M. J., Danila, D. C., Slovin, S. F., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5801 · Cited by 667
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Cancer prevention from the perspective of global cancer burden patterns
Nagai, H., & Kim, Y. H. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.75 · Cited by 621
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Saâda-Bouzid, E., Defaucheux, C., Karabajakian, A., Coloma, V. P., Servois, V., Paoletti, X., Even, C., Fayette, J., Guigay, J., Loirat, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx178 · Cited by 596
Cottrell, T. R., Thompson, E. D., Forde, P. M., Stein, J. E., Duffield, A. S., Anagnostou, V., Rekhtman, N., Anders, R. A., Cuda, J. D., Illei, P. B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy218 · Cited by 592
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 571
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Shen, X., & Zhao, B. (2018) · BMJ · doi:10.1136/bmj.k3529 · Cited by 559
Xu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 558
Zheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., Jiang, W., Cai, S., Zhao, P., Song, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0650-9 · Cited by 550
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Yarchoan, M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T. T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 545
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541 · cited 1×
“lymphocyte count (ALC), absolute neutrophil count (ANC), and absolute eosinophil count (AEC), were related to survival in melanoma patients undergoing treatment with immune checkpoint inhibitor therapy [115, 116].”
BackgroundApplication of PD-1 Blockade in Cancer Immunotherapy
Wu, X., Gu, Z., Chen, Y., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 531
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 504
Capone, M., Giannarelli, D., Mallardo, D., Madonna, G., Festino, L., Grimaldi, A. M., Vanella, V., Simeone, E., Paone, M., Palmieri, G., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0383-1 · Cited by 497 · cited 1×
“Several studies highlighted that elevated pretreatment neutrophil to lymphocyte ratio (NLR) values were associated with shorter overall survival in patients with metastatic melanoma treated with either ipilimumab or nivolumab [112, 113].”
BackgroundAbdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
Niemeijer, A. N., Leung, D., Huisman, M. C., Bahce, I., Hoekstra, O. S., van Dongen, G. A. M. S., Boellaard, R., Du, S., Hayes, W., Smith, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07131-y · Cited by 484
CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Miliotou, A. N., & Papadopoulou, L. C. (2018) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180418095526 · Cited by 480
Danaher, P., Warren, S., Lu, R., Samayoa, J., Sullivan, A., Pekker, I., Wallden, B., Marincola, F. M., & Cesano, A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0367-1 · Cited by 421
Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0348-2 · Cited by 418
Lee, H.-H., Wang, Y.-N., Xia, W., Chen, C.-H., Rau, K.-M., Ye, L., Wei, Y., Chou, C.-K., Wang, S.-C., Yan, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.008 · Cited by 405
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 401
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Nowicki, T. S., Hu-Lieskovan, S., & Ribas, A. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000303 · Cited by 397
Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
Nishino, M., Sholl, L. M., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1505197 · Cited by 373
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Implications of the tumor immune microenvironment for staging and therapeutics
Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., Baras, A. S., Patel, S. S., Anders, R. A., Rimm, D. L., et al. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.156 · Cited by 358
The role of the PD‐1 pathway in autoimmunity and peripheral tolerance
Fife, B. T., & Pauken, K. E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05919.x · Cited by 355
Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215
Georges, S. A., Biery, M. C., Kim, S.-Y., Schelter, J. M., Guo, J., Chang, A. N., Jackson, A. L., Carleton, M. O., Linsley, P. S., Cleary, M. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1846 · Cited by 348
Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342 · cited 2×
“The expression of PDL-1 is currently a validated and important predictive biomarker; however, this alone is not sufficient and specific enough for determining which patients should be offered PD-1/L1 blockade therapy [59, 79, 80].”
BackgroundImmune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339 · cited 1×
“Clinicians are encouraged to consider balancing the risks of toxicity with potential benefits and to make such decisions based on data from challenging patient populations, such as patients with autoimmune disorders, organ transplant, chronic viral infections, ongoing immunosuppressant use, organ dysfunction, pregnanc…”
BackgroundProgrammed Death Ligand 2 in Cancer-Induced Immune Suppression
Rozali, E. N., Hato, S. V., Robinson, B. W., Lake, R. A., & Lesterhuis, W. J. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/656340 · Cited by 328
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., & Tartour, E. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 324
Overview of methodologies for T-cell receptor repertoire analysis
Rosati, E., Dowds, C. M., Liaskou, E., Henriksen, E. K. K., Karlsen, T. H., & Franke, A. (2017) · BMC Biotechnology · doi:10.1186/s12896-017-0379-9 · Cited by 322
Läubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, E., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41068 · Cited by 309
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
The intracellular signalosome of PD-L1 in cancer cells
Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 292
The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function
Pompura, S. L., & Dominguez-Villar, M. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0817-349r · Cited by 288
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Kim, C. G., Kim, K. H., Pyo, K.-H., Xin, C.-F., Hong, M. H., Ahn, B.-C., Kim, Y., Choi, S. J., Yoon, H. I., Lee, J. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz123 · Cited by 282
Topography of cancer-associated immune cells in human solid tumors
Kather, J. N., Suarez-Carmona, M., Charoentong, P., Weis, C.-A., Hirsch, D., Bankhead, P., Horning, M., Ferber, D., Kel, I., Herpel, E., et al. (2018) · eLife · doi:10.7554/elife.36967 · Cited by 280
Han, J., Duan, J., Bai, H., Wang, Y., Wan, R., Wang, X., Chen, S., Tian, Y., Wang, D., Fei, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0398 · Cited by 264
The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
Ostrand-Rosenberg, S., Horn, L. A., & Haile, S. T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401572 · Cited by 228
Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review)
Shi, X., Wang, J., Lei, Y., Cong, C., Tan, D., & Zhou, X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10121 · Cited by 226
Higgs, B. W., Morehouse, C. A., Streicher, K., Brohawn, P. Z., Pilataxi, F., Gupta, A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3451 · Cited by 220
Salem, M. E., Puccini, A., Grothey, A., Raghavan, D., Goldberg, R. M., Xiu, J., Korn, W. M., Weinberg, B. A., Hwang, J. J., Shields, A. F., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0735 · Cited by 217
Udall, M., Rizzo, M., Kenny, J., Doherty, J., Dahm, S., Robbins, P., & Faulkner, E. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0689-9 · Cited by 208
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Wang, H., Kaur, G., Sankin, A. I., Chen, F., Guan, F., & Zang, X. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0746-1 · Cited by 202
Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0008-8 · Cited by 200
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 193
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
Braun, D. A., Burke, K. P., & Van Allen, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0066 · Cited by 179
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 175
Lugowska, I. A., Teterycz, P., & Rutkowski, P. L. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73889 · Cited by 171
PD-1 blockade enhances the vaccination-induced immune response in glioma
Antonios, J. P., Soto, H., Everson, R. G., Orpilla, J., Moughon, D., Shin, N., Sedighim, S., Yong, W. H., Li, G., Cloughesy, T. F., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87059 · Cited by 170
Wang, B., Zhang, W., Jankovic, V., Golubov, J., Poon, P., Oswald, E. M., Gurer, C., Wei, J., Ramos, I., Wu, Q., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat7061 · Cited by 167 · cited 1×
“Tumors cause overstimulation of the PD-1/L1 signaling pathway to reduce T cell activation and antigen-specific T cell immune response, thereby bypassing immune surveillance [9, 18, 19].”
BackgroundImmune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges
Kyi, C., & Postow, M. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0002 · Cited by 165
Danilova, L., Wang, H., Sunshine, J., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 161
Su, Q., Zhu, E. C., Wu, J.-B., Li, T., Hou, Y.-L., Wang, D.-Y., & Gao, Z.-H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00108 · Cited by 161
Zhao, R., Song, Y., Wang, Y., Huang, Y., Li, Z., Cui, Y., Yi, M., Xia, L., Zhuang, W., Wu, X., et al. (2019) · Cell Proliferation · doi:10.1111/cpr.12571 · Cited by 161
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, J., Gao, Z., Li, X., Dong, L., Han, W., & Nie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22690 · Cited by 158
Single Cell T Cell Receptor Sequencing: Techniques and Future Challenges
De Simone, M., Rossetti, G., & Pagani, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01638 · Cited by 157
CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
Brunner-Weinzierl, M. C., & Rudd, C. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02737 · Cited by 153
Cryoablation and immunotherapy: an overview of evidence on its synergy
Aarts, B. M., Klompenhouwer, E. G., Rice, S. L., Imani, F., Baetens, T., Bex, A., Horenblas, S., Kok, M., Haanen, J. B. A. G., Beets-Tan, R. G. H., et al. (2019) · Insights into Imaging · doi:10.1186/s13244-019-0727-5 · Cited by 152
Zaragoza, J., Caille, A., Beneton, N., Bens, G., Christiann, F., Maillard, H., & Machet, L. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14155 · Cited by 150
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s135157 · Cited by 144 · cited 2×
“Apart from melanoma, PD-1 inhibitors have also shown clinical efficacy in both solid and liquid cancers such as bladder, pancreatic, and non-small-cell lung cancer (NSCLC), follicular B cell, and non-Hodgkin lymphoma [45] (Table 2).”
BackgroundCader, F. Z., Hu, X., Goh, W. L., Wienand, K., Ouyang, J., Mandato, E., Redd, R., Lawton, L. N., Chen, P.-H., Weirather, J. L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1006-1 · Cited by 142
The intimate relationship between gut microbiota and cancer immunotherapy
Elkrief, A., Derosa, L., Zitvogel, L., Kroemer, G., & Routy, B. (2019) · Gut Microbes · doi:10.1080/19490976.2018.1527167 · Cited by 141
Tumor fraction in cell-free DNA as a biomarker in prostate cancer
Choudhury, A. D., Werner, L., Francini, E., Wei, X. X., Ha, G., Freeman, S. S., Rhoades, J., Reed, S. C., Gydush, G., Rotem, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122109 · Cited by 139
Joller, N., & Kuchroo, V. K. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_62 · Cited by 133
Noninvasive PET Imaging of T cells
Wei, W., Jiang, D., Ehlerding, E. B., Luo, Q., & Cai, W. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.03.009 · Cited by 125
Kleponis, J., Skelton, R. A., & Zheng, L. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0046 · Cited by 125
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelínek, T., Paiva, B., & Hájek, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02431 · Cited by 124
Opportunistic infections in patients treated with immunotherapy for cancer
Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B., & Postow, M. A. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-19 · Cited by 119
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mössner, R., Ugurel, S., Zimmer, L., Gutzmer, R., & for the “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO) (2016) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 118
Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review
Myers, G. (2018) · Current Oncology · doi:10.3747/co.25.4235 · Cited by 116
The Future of Immunotherapy: A 20-Year Perspective
Wraith, D. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01668 · Cited by 111
Khan, M., Lin, J., Liao, G., Tian, Y., Liang, Y., Li, R., Liu, M., & Yuan, Y. (2018) · Medicine · doi:10.1097/md.0000000000011936 · Cited by 107
MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1
Li, Y., Xie, J., Xu, X., Wang, J., Ao, F., Wan, Y., & Zhu, Y. (2013) · Protein & Cell · doi:10.1007/s13238-012-2081-y · Cited by 107
Wu, J., Hong, D., Zhang, X., Lu, X., & Miao, J. (2017) · Scientific Reports · doi:10.1038/srep44173 · Cited by 106
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0150-0 · Cited by 96 · cited 2×
“A perfect example in this regard is the combination treatment of anti-CTLA-4 and anti-PD-1 antibodies, which has proved to be a feasible strategy significantly increasing overall response rate and demonstrating an acceptable safety profile compared with anti-PD-1 or anti-CTLA-4 monotherapy [58].”
BackgroundSgambato, A., Casaluce, F., C. Sacco, P., Palazzolo, G., Maione, P., Rossi, A., Ciardiello, F., & Gridelli, C. (2016) · Current Drug Safety · doi:10.2174/1574886311207040289 · Cited by 94
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Wang, D., Lin, J., Yang, X., Long, J., Bai, Y., Yang, X., Mao, Y., Sang, X., Seery, S., & Zhao, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0730-9 · Cited by 93
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
Cretella, D., Digiacomo, G., Giovannetti, E., & Cavazzoni, A. (2019) · Cancers · doi:10.3390/cancers11091318 · Cited by 92
Aguiar, P. N., Perry, L. A., Penny‐Dimri, J. C., Babiker, H. M., Tadokoro, H., de Mello, R. A., & Junior, G. L. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx305 · Cited by 91
Shukuya, T., Ghai, V., Amann, J. M., Okimoto, T., Shilo, K., Kim, T., Wang, K., & Carbone, D. P. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.022 · Cited by 89
Klemen, N. D., Wang, M., Feingold, P. L., Cooper, K., Pavri, S. N., Han, D., Detterbeck, F. C., Boffa, D. J., Khan, S. A., Olino, K. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0672-3 · Cited by 85
Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.
Dimberu, P., & Leonhardt, R. M. (2011) · PubMed Central · Cited by 81
Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer
Fan, J., Yin, Z., Xu, J., Wu, F., Huang, Q., Yang, L., Jin, Y., & Yang, G. (2019) · Genomics · doi:10.1016/j.ygeno.2019.11.019 · Cited by 81
Application of Mass Cytometry (CyTOF) for Functional and Phenotypic Analysis of Natural Killer Cells
Kay, A. W., Strauss‐Albee, D. M., & Blish, C. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3684-7_2 · Cited by 79
Recharacterizing Tumor-Infiltrating Lymphocytes by Single-Cell RNA Sequencing
Zhang, L., & Zhang, Z. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0658 · Cited by 79
Halvorsen, A. R., Sandhu, V., Sprauten, M., Flote, V. G., Kure, E. H., Brustugun, O. T., & Helland, Å. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1465585 · Cited by 78
Clinical trials of CAR-T cells in China
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0535-7 · Cited by 75
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
Sehgal, K., Portell, A., Ivanova, E. V., Lizotte, P. H., Mahadevan, N. R., Greene, J. R., Vajdi, A., Gurjao, C., Teceno, T., Taus, L. J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135038 · Cited by 74
Mall, C., Sckisel, G. D., Proia, D. A., Mirsoian, A., Grossenbacher, S. K., Pai, C.-C. S., Chen, M., Monjazeb, A. M., Kelly, K., Blazar, B. R., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1075114 · Cited by 71
Li, X., Warren, S. E., Pelekanou, V., Wali, V. B., Cesano, A., Liu, M., Danaher, P. J., Elliott, N., Nahleh, Z. A., Hayes, D. F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0563-7 · Cited by 68
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
Drug response to PD-1/PD-L1 blockade: based on biomarkers
Chen, Q., Li, T., & Yue, W. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s168313 · Cited by 58
Oral immunotherapy for food allergy: mechanisms and role in management
Nowak-Wegrzyn, A. H., & Albin, S. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12382 · Cited by 56
Cancer immunotherapy with CAR-T cells – behold the future
Graham, C., Hewitson, R., Pagliuca, A., & Benjamin, R. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-4-324 · Cited by 56
Budczies, J., Mechtersheimer, G., Denkert, C., Klauschen, F., Mughal, S. S., Chudasama, P., Bockmayr, M., Jöhrens, K., Endris, V., Lier, A., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1279777 · Cited by 55
Domschke, C., Ge, Y., Bernhardt, I., Schott, S., Keim, S., Juenger, S., Bucur, M., Mayer, L., Blumenstein, M., Rom, J., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1414-x · Cited by 51
Jennifer, Kleponis, Richard, Skelton, Lei, L., & Zheng, Z. (2015) · 癌症生物学与医学:英文版 · Cited by 51
Schütz, F., Ehlert, K., Ge, Y., Schneeweiß, A., Rom, J., Inzkirweli, N., Sohn, C., Schirrmacher, V., & Beckhove, P. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0605-3 · Cited by 48
Budczies, J., Denkert, C., Győrffy, B., Schirmacher, P., & Stenzinger, A. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0308-8 · Cited by 47
Shen, K., Cui, J., Wei, Y., Chen, X., Liu, G., Gao, X., Li, W., Lü, H., Zhan, P., Lv, T., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.72 · Cited by 46
Sitaram, P., Uyemura, B. S., Malarkannan, S., & Riese, M. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235821 · Cited by 45
Noninvasive Imaging of Cancer Immunotherapy
Abousaway, O., Rakhshandehroo, T., den Abbeele, A. D. V., Kircher, M. F., & Rashidian, M. (2020) · Nanotheranostics · doi:10.7150/ntno.50860 · Cited by 45
Xie, X., Liu, J., Yang, H., Chen, H., Zhou, S., Lin, H., Liao, Z., Ding, Y., Ling, L., & Wang, X. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1639057 · Cited by 44
Primary Immunodeficiency Diseases: Current and Emerging Therapeutics
Marciano, B. E., & Holland, S. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00937 · Cited by 43
Leprieur, E. G., Hélias‐Rodzewicz, Z., Kamga, P. T., Costantini, A., Julié, C., Corjon, A., Duménil, C., Dumoulin, J., Giraud, V., Labrune, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000527 · Cited by 42
Systemic therapy of metastatic melanoma: on the road to cure.
Bhatia, S., Tykodi, S. S., Lee, S. M., & Thompson, J. A. (2015) · PubMed · Cited by 39
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.
Jazirehi, A. R., Lim, A., & Dinh, T. (2016) · PubMed Central · Cited by 37
Mechanisms of Resistance to Immune Checkpoint Antibodies
Ramos, R. N., Piaggio, E., & Romano, E. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_11 · Cited by 34
Immunological effect of local ablation combined with immunotherapy on solid malignancies
Takahashi, Y., Matsutani, N., Nakayama, T., Dejima, H., Uehara, H., & Kawamura, M. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0216-5 · Cited by 31
Pike, E., Hamidi, V., Sæterdal, I., Odgaard‐Jensen, J., & Klemp, M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014880 · Cited by 30
Tomela, K., Pietrzak, B., SCHMIDT, M. T., & Mackiewicz, A. A. (2020) · Life · doi:10.3390/life10100219 · Cited by 25
Perceptions of Cancer Risk and Cause of Cancer Risk in Korean Adults
Kye, S. Y., Park, E. Y., Oh, K., & Park, K. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.024 · Cited by 20
Pembrolizumab for the treatment of advanced melanoma
Burns, M. C., O’donnell, A., & Puzanov, I. J. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1191348 · Cited by 20
MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma
Nakahara, S., Fukushima, S., Okada, E., Morinaga, J., Kubo, Y., Tokuzumi, A., Matsumoto, S., Tsuruta, M., Kimura, T., Kuriyama, H., et al. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.11.010 · Cited by 20
FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
(2020) · Case Medical Research · doi:10.31525/cmr-264c778 · Cited by 17
Kopetz, S., Lonardi, S., McDermott, R., Aglietta, M., Hendlisz, A., Morse, M. A., Leach, J. W., Neyns, B., Chan, E. W., Chen, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3548 · Cited by 9
Immunotherapy for Primary Immunodeficiency Diseases
Wood, P. M. D. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.010 · Cited by 8
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy
Bonanno, L., Pavan, A., Attili, I., Pasello, G., & Guarneri, V. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2033 · Cited by 8
FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
(2020) · Case Medical Research · doi:10.31525/cmr-264c772 · Cited by 6
Weibo, P., & Ye, Z. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.01.038 · Cited by 5
Research works printed but not linked: 1
- Z. R. Kelly, 2019, The Financial and Physical Toxicity of Immune Checkpoint Inhibitors in Cancer Alexandria
Cited by
T cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 604
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Cui, J.-W., Li, Y., Yang, Y., Yang, H.-K., Dong, J.-M., Xiao, Z.-H., He, X., Guo, J.-H., Wang, R.-Q., Dai, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116203 · Cited by 184
Rizzo, A., Ricci, A. D., Federico, A. D., Frega, G., Palloni, A., Tavolari, S., & Brandi, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.803133 · Cited by 110
Evolution of cell therapy for renal cell carcinoma
Wang, Y., Suarez, E. R., Kastrunes, G. M., de Campos, N. S. P., Abbas, R., Pivetta, R. S., Murugan, N., Chalbatani, G. M., D’Andrea, V. D., & Marasco, W. A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01911-x · Cited by 126
Metadata
- Authors
- Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N.
- Affiliations
- Universal Scientific Education and Research Network (IR)
- Iran University of Medical Sciences (IR)
- Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
- Corresponding author
- Rezaei, Nima
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2021-02-22
- Volume
- 2021
- Pages
- 1-15
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- PMC
- PMC7925068
- OpenAlex
- W3129917327
- Cited by
- 136
- References
- 169
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 33 · 2023: 29 · 2022: 29 · 2021: 11
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Immunology Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-1/PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy, predictive biomarkers, immune-related adverse events, autoimmune myocarditis, immunotherapy efficacy, hematologic malignancies, solid tumors
- MeSH terms
- Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Immune Checkpoint Proteins, Animals, Humans, Immunotherapy, Neoplasms, Biomarkers, Tumor, Signal Transduction, Treatment Outcome, Molecular Targeted Therapy, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.